Trial reportThe Journal of infection2026
Genotype distribution of human papillomavirus (HPV) types in oral gargle specimens among men living with HIV in Mexico, Brazil, and Puerto Rico: A cross-sectional study.
Trial report in The Journal of infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04255849 (Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nine-valent HPV Vaccine to Prevent Persistent Oral HPV Infection in Men Living With HIV
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
objectivesAssess the distribution of oral HPV genotypes and examine their associations with age and HIV-related factors among men living with HIV.
methodsThis cross-sectional study analyzed baseline data from a randomized, double-blinded, placebo-controlled Phase III trial ('ULACNet-201'; NCT04255849) assessing the 9vHPV vaccine's efficacy in PLWH. Participants included men aged 20-50 years from Brazil, Mexico, and Puerto Rico, on antiretroviral therapy for ≥6 months. Oral HPV genotypes were assessed using the SPF
resultsAmong 700 participants, oral HPV was detected in 27.9%, with HR-HPV detection at 11.0%. 4vHPV and 9vHPV types were detected in 4.9% and 8.9% participants, respectively. The most detected HR-HPV types were HPV 16 (2.4%), HPV 33 (2.0%), and HPV 52 (2.0%). No significant age-specific differences in oral HPV detected were observed. Higher detection rates of any HPV and HR-HPV were observed among participants with baseline CD4 counts below 200 cells/mm³ or a history of AIDS-defining conditions.
conclusionsOral HPV genotyping in men with HIV reveals distinct oncogenic patterns, underscoring the need to monitor long-term OPSCC risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.